Fig. 8

Clinical relevance of lung cancer PDO-based HTS analysis and CODRP index analysis. (A) The LC_01T patient was prescribed alectinib after the tumor recurred and showed a partial response (PR), and as a result of drug sensitivity test using LC_01T organoid derived from tumor tissue, showed a sensitive response to alectinib. (B) After being diagnosed with lung cancer accompanied by MPE, the LC_03PE patient was prescribed alectinib and showed PR; a drug sensitivity test using LC_03PE organoid derived from MPE showed a sensitive response to alectinib. (C) LC_02T patient was prescribed brigatinib after tumor tissue removal surgery and maintained stable disease (SD) without recurrence; drug sensitivity tests using LC_02T organoid derived from tumor tissues showed a sensitive response to brigatinib. (D) After being diagnosed with lung cancer accompanied by MPE and brain metastases, the LC_09PE patient was prescribed brigatinib and showed PR; a drug sensitivity test using LC_03PE organoid derived from MPE showed a sensitive response to brigatinib